SFMG Wealth Advisors’s Edgewise Therapeutics EWTX Stock Holding History

SFMG Wealth Advisors’s Portfolio EWTX Stock Details EWTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-10,000	Closed	-$315K	–	350
2026 Q1	$315K	Hold	10,000	–	–	0.02%	244
2025 Q4	$248K	Hold	10,000	–	–	0.02%	265
2025 Q3	$162K	Hold	10,000	–	–	0.01%	289
2025 Q2	$131K	Hold	10,000	–	–	0.01%	268
2025 Q1	$220K	Hold	10,000	–	–	0.02%	247
2024 Q4	$267K	Hold	10,000	–	–	0.02%	217
2024 Q3	$267K	Hold	10,000	–	–	0.02%	213
2024 Q2	$180K	Hold	10,000	–	–	0.02%	248
2024 Q1	$182K	Hold	10,000	–	–	0.02%	257
2023 Q4	$109K	Hold	10,000	–	–	0.01%	260
2023 Q3	$57.3K	Hold	10,000	–	–	0.01%	243
2023 Q2	$77.5K	Hold	10,000	–	–	0.01%	242
2023 Q1	$66.7K	Hold	10,000	–	–	0.01%	250
2022 Q4	$89.4K	Hold	10,000	–	–	0.01%	243
2022 Q3	$107K	Sell	10,000 -100	-1%	-$1.01K	0.01%	234
2022 Q2	$80K	Hold	10,100	–	–	0.01%	256
2022 Q1	$98K	Buy	+10,100	New	+$130K	0.01%	283

Other funds holding EWTX

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

SFMG Wealth Advisors's EWTX Position: Q2 2026 in Review

SFMG Wealth Advisors sold out of Edgewise Therapeutics (EWTX) in Q2 2026, closing a stake of 10,000 shares — an estimated $315K sold.

SFMG Wealth Advisors first reported a position in EWTX in Q1 2022 and held it in 17 quarters. The position peaked at $315K in Q1 2026. 227 funds tracked by Wall St. Rank hold EWTX as of Q2 2026.

SFMG Wealth Advisors reported no remaining Edgewise Therapeutics position as of Q2 2026 after selling out during the quarter.
SFMG Wealth Advisors sold 10,000 Edgewise Therapeutics shares in Q2 2026, an estimated $315K.
SFMG Wealth Advisors first reported a position in Edgewise Therapeutics in Q1 2022 and held it in 17 quarters.
SFMG Wealth Advisors's Edgewise Therapeutics position peaked at $315K in Q1 2026.
227 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q2 2026.

Based on SFMG Wealth Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.